Cargando…
Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358352/ https://www.ncbi.nlm.nih.gov/pubmed/32733794 http://dx.doi.org/10.3389/fonc.2020.00989 |
_version_ | 1783558835032555520 |
---|---|
author | König, Laila Haering, Peter Lang, Clemens Splinter, Mona von Nettelbladt, Bastian Weykamp, Fabian Hoegen, Philipp Lischalk, Jonathan W. Herfarth, Klaus Debus, Jürgen Hörner-Rieber, Juliane |
author_facet | König, Laila Haering, Peter Lang, Clemens Splinter, Mona von Nettelbladt, Bastian Weykamp, Fabian Hoegen, Philipp Lischalk, Jonathan W. Herfarth, Klaus Debus, Jürgen Hörner-Rieber, Juliane |
author_sort | König, Laila |
collection | PubMed |
description | Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of randomizing patients between modalities. The objective of the current study is to calculate the risk for secondary malignancies following PRT and photon-based intensity-modulated radiotherapy (IMRT). Materials and Methods: Twenty-three patients (16 female and seven male), previously treated with active scanning PRT for malignant mediastinal lymphoma at Heidelberg Ion Beam Therapy Center, were retrospectively re-planned using helical photon IMRT. The risk for radiation-induced secondary malignancies was estimated and evaluated using two distinct prediction models (1–4). Results: According to the Dasu model, the median absolute total risk for tumor induction following IMRT was 4.4% (range, 3.3–5.8%), 9.9% (range, 2.0–27.6%), and 1.0% (range, 0.5–1.5%) for lung, breast, and esophageal cancer, respectively. For PRT, it was significantly lower for the aforementioned organs at 1.6% (range, 0.7–2.1%), 4.5% (range, 0.0–15.5), and 0.8% (range, 0.0–1.6%), respectively (p ≤ 0.01). The mortality risk from secondary malignancies was also significantly reduced for PRT relative to IMRT at 1.1 vs. 3.1% (p ≤ 0.001), 0.9 vs. 1.9% (p ≤ 0.001), and 0.7 vs. 1.0% (p ≤ 0.001) for lung, breast, and esophageal tumors, respectively. Using the Schneider model, a significant risk reduction of 54.4% (range, 32.2–84.0%), 56.4% (range, 16.0–99.4%), and 24.4% (range, 0.0–99.0%) was seen for secondary lung, breast, and esophageal malignancies, favoring PRT vs. X-ray-based IMRT (p ≤ 0.01). Conclusion: Based on the two prediction models, PRT for malignant mediastinal lymphoma is expected to reduce the risk for radiation-induced secondary malignancies compared with the X-ray-based IMRT. The young age and the long natural history of patients diagnosed with mediastinal lymphoma predisposes them to a high risk of secondary malignancies following curative radiotherapy treatment and, as a consequence, potentially reducing this risk by utilizing advanced radiation therapy techniques such as PRT should be considered. |
format | Online Article Text |
id | pubmed-7358352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73583522020-07-29 Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk König, Laila Haering, Peter Lang, Clemens Splinter, Mona von Nettelbladt, Bastian Weykamp, Fabian Hoegen, Philipp Lischalk, Jonathan W. Herfarth, Klaus Debus, Jürgen Hörner-Rieber, Juliane Front Oncol Oncology Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of randomizing patients between modalities. The objective of the current study is to calculate the risk for secondary malignancies following PRT and photon-based intensity-modulated radiotherapy (IMRT). Materials and Methods: Twenty-three patients (16 female and seven male), previously treated with active scanning PRT for malignant mediastinal lymphoma at Heidelberg Ion Beam Therapy Center, were retrospectively re-planned using helical photon IMRT. The risk for radiation-induced secondary malignancies was estimated and evaluated using two distinct prediction models (1–4). Results: According to the Dasu model, the median absolute total risk for tumor induction following IMRT was 4.4% (range, 3.3–5.8%), 9.9% (range, 2.0–27.6%), and 1.0% (range, 0.5–1.5%) for lung, breast, and esophageal cancer, respectively. For PRT, it was significantly lower for the aforementioned organs at 1.6% (range, 0.7–2.1%), 4.5% (range, 0.0–15.5), and 0.8% (range, 0.0–1.6%), respectively (p ≤ 0.01). The mortality risk from secondary malignancies was also significantly reduced for PRT relative to IMRT at 1.1 vs. 3.1% (p ≤ 0.001), 0.9 vs. 1.9% (p ≤ 0.001), and 0.7 vs. 1.0% (p ≤ 0.001) for lung, breast, and esophageal tumors, respectively. Using the Schneider model, a significant risk reduction of 54.4% (range, 32.2–84.0%), 56.4% (range, 16.0–99.4%), and 24.4% (range, 0.0–99.0%) was seen for secondary lung, breast, and esophageal malignancies, favoring PRT vs. X-ray-based IMRT (p ≤ 0.01). Conclusion: Based on the two prediction models, PRT for malignant mediastinal lymphoma is expected to reduce the risk for radiation-induced secondary malignancies compared with the X-ray-based IMRT. The young age and the long natural history of patients diagnosed with mediastinal lymphoma predisposes them to a high risk of secondary malignancies following curative radiotherapy treatment and, as a consequence, potentially reducing this risk by utilizing advanced radiation therapy techniques such as PRT should be considered. Frontiers Media S.A. 2020-07-07 /pmc/articles/PMC7358352/ /pubmed/32733794 http://dx.doi.org/10.3389/fonc.2020.00989 Text en Copyright © 2020 König, Haering, Lang, Splinter, von Nettelbladt, Weykamp, Hoegen, Lischalk, Herfarth, Debus and Hörner-Rieber. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology König, Laila Haering, Peter Lang, Clemens Splinter, Mona von Nettelbladt, Bastian Weykamp, Fabian Hoegen, Philipp Lischalk, Jonathan W. Herfarth, Klaus Debus, Jürgen Hörner-Rieber, Juliane Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title_full | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title_fullStr | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title_full_unstemmed | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title_short | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk |
title_sort | secondary malignancy risk following proton vs. x-ray treatment of mediastinal malignant lymphoma: a comparative modeling study of thoracic organ-specific cancer risk |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358352/ https://www.ncbi.nlm.nih.gov/pubmed/32733794 http://dx.doi.org/10.3389/fonc.2020.00989 |
work_keys_str_mv | AT koniglaila secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT haeringpeter secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT langclemens secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT splintermona secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT vonnettelbladtbastian secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT weykampfabian secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT hoegenphilipp secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT lischalkjonathanw secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT herfarthklaus secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT debusjurgen secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk AT hornerrieberjuliane secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk |